Enecadin

Drug Profile

Enecadin

Alternative Names: NS 7; ZK 228326

Latest Information Update: 17 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nippon Shinyaku
  • Class Neuroprotectants; Pyrimidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Calpain inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurological disorders; Stroke

Most Recent Events

  • 01 Feb 2006 Phase-II clinical trials in Stroke in Germany (unspecified route)
  • 07 Oct 2004 Enecadin has been licensed to PAION worldwide except Japan
  • 21 Jul 2003 Discontinued - Phase-II for Stroke in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top